Literature DB >> 7587962

pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.

J H Lin1, I W Chen, K J Vastag, D Ostovic.   

Abstract

L-735,524, a potent and specific inhibitor of human immunodeficiency virus protease, is currently under investigation for the treatment of acquired immunodeficiency syndrome. The aqueous solubility of L-735,524 was pH-dependent, > 100 mg/ml at pH below 3.5 and 0.03 mg/ml at pH 6. When L-735,524 was given orally as a suspension in 0.5% methocel (pH 6.5) at 10 mg/kg, the bioavailability was approximately 16% for both dogs and rats. When the same dose of the drug was administered in 0.05 M citric acid (pH 2.5), the bioavailability increased 4.5-fold in dogs (72%), but only slightly in rats (24%). The pH- and species-dependent differences in bioavailability observed in rats and dogs may be because of differences in the rate of gastric acid secretion and in the magnitude of hepatic first-pass effect. Gastric acid secretion is poor in dogs but substantial in rats. When L-735,524 was administered in 0.5% methocel, a large portion of the drug in dogs, but not in rats, remained undissolved, resulting in poor absorption in dogs. On the other hand, when L-735,524 was administered in citric acid, most of the drug would be in solution allowing for better absorption in dogs. The hypothesis of pH-dependent absorption was further supported by the findings that absorption was significantly increased in dogs after feeding, but substantially decreased in rats after pretreatment with famotidine, a potent H2-receptor antagonist. L-735,524 underwent an extensive first-pass metabolism in rats, but not in dogs.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7587962

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Pharmacokinetic enhancement of protease inhibitor therapy.

Authors:  Jennifer R King; Heather Wynn; Richard Brundage; Edward P Acosta
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  Targeting anti-HIV drugs to the CNS.

Authors:  Kavitha S Rao; Anuja Ghorpade; Vinod Labhasetwar
Journal:  Expert Opin Drug Deliv       Date:  2009-08       Impact factor: 6.648

4.  Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients.

Authors:  P L Carver; D Fleisher; S Y Zhou; D Kaul; P Kazanjian; C Li
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

5.  Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin.

Authors:  Bharat D Damle; Vanaja Mummaneni; Sanjeev Kaul; Catherine Knupp
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

6.  Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.

Authors:  D M Burger; A M van Rossum; P W Hugen; M H Suur; N G Hartwig; S P Geelen; H J Scherpbier; R M Hoetelmans; A G Vulto; R de Groot
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  Mechanism of indinavir-induced hyperbilirubinemia.

Authors:  S D Zucker; X Qin; S D Rouster; F Yu; R M Green; P Keshavan; J Feinberg; K E Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

8.  Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.

Authors:  A Hsu; G R Granneman; G Cao; L Carothers; A Japour; T El-Shourbagy; S Dennis; J Berg; K Erdman; J M Leonard; E Sun
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.

Authors:  Hiba L Tappouni; John C Rublein; Brian J Donovan; Stephanie B Hollowell; Hsiao-Chuan Tien; Sherene S Min; Dickens Theodore; Naser L Rezk; Philip C Smith; Melanie N Tallman; Ralph H Raasch; Angela D M Kashuba
Journal:  Am J Health Syst Pharm       Date:  2008-03-01       Impact factor: 2.637

10.  Influence of indocyanine green on plasma disappearance and biliary excretion of a synthetic thrombin inhibitor of the 3-amidinophenyl-alanine piperazide-type in rats.

Authors:  J Hauptmann; J Stürzebecher
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.